Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Michael A. Chapman(Toronto Metropolitan University), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Karthink Ramasamy(Oxford University Hospitals NHS Trust), Selina J Chavda(University College London), William Wilson(Cancer Research UK), María Cuadrado(University College London), Jonathan Sive(University College London Hospitals NHS Foundation Trust)
Cited by 5
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719